Clinical Trials Logo

Fatty Liver clinical trials

View clinical trials related to Fatty Liver.

Filter by:

NCT ID: NCT03863574 Completed - Clinical trials for Non Alcoholic Steatohepatitis

Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis

EVIDENCES VI
Start date: June 12, 2019
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled study to evaluate safety and efficacy of Saroglitazar Magnesium 2 mg and 4 mg in patients with NASH. This study will be initiated after obtaining the approvals of Institutional Ethics Committee/Institutional Review Board (IEC/IRB) and the local regulatory authority.

NCT ID: NCT03861819 Completed - Liver Diseases Clinical Trials

Feasibility of VIIT in Adults With NASH

Start date: January 1, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether patients with stage 1-3 NASH-related fibrosis are able to complete a single vigorous-intensity interval training (VIIT) session on an indoor rowing machine and provide blood samples before and afterwards. The results of this study will provide the foundation for future research on the role of VIIT in treating NASH.

NCT ID: NCT03858920 Completed - Clinical trials for NASH - Nonalcoholic Steatohepatitis

The Liver in the World Trade Center Health Program General Responder Cohort and Controls

Start date: May 8, 2018
Phase:
Study type: Observational

This project investigates whether exposure to the World Trade Center Attack is a risk factor for liver injury.

NCT ID: NCT03851627 Recruiting - Fatty Liver Clinical Trials

Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadism

Test2Func
Start date: January 25, 2022
Phase: Phase 4
Study type: Interventional

The epidemics of obesity, MeTSy, T2DM and CVD are increasing worldwide. Non-alcoholic fatty liver disease (NAFLD) is becoming recognized as a condition possibly involved in the pathogenesis of these diseases. The prevailing hypothesis for NAFLD pathogenesis is the 'two-hit' model, with insulin resistance and hyperinsulinemia playing essential roles, which have a plethora of effects on hepatic lipid metabolism and can lead to accumulation of triglycerides in hepatocytes. Accepted treatment for NAFLD is lifestyle modifications. Sex hormones might be relevant in T2DM development and treatment. Low testosterone (T) has deteriorating effects on glucose levels, and aggravates in obesity as aromatization of T is enhanced. T deficiency is related to increases of visceral fat accumulation and associated with development of NAFLD. T replacement might be a successful way in hypogonadism to treat obesity and counteract progression of MEtSy,T2DM or CVD driven by visceral fat accumulation or NAFLD. Primary Objective To investigate the effects on hepatic lipid content reduction of a therapy with Testosterone undecanoate 1000mg compared to placebo given for 52 weeks in patients with type 2 diabetes mellitus and hypogonadism.

NCT ID: NCT03850886 Completed - Clinical trials for Non Alcoholic Fatty Liver Disease

Nicotinamide in Non-Alcoholic Fatty Liver Disease Patients

Start date: January 15, 2019
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of Niacinamide supplementation on clinical outcome of fatty liver patients having type II DM through measurement of the following before and after Niacinamide administration: Liver enzymes, Lipid profie, HOMA-IR, Oxidative stress markers and endothelial dysfunction marker. Fibroscan with CAP will be done at baseline and at the end of the trial. Also, Evaluation of quality of life of patients before and after Niacinamide administration using Chronic Liver Disease questionnaire.

NCT ID: NCT03849729 Completed - Obesity Clinical Trials

Effectiveness and Tolerability of Phentermine in Patients Under Bariatric Surgery

Start date: March 1, 2018
Phase: Phase 4
Study type: Interventional

Surgical management of Morbid Obesity is increasingly frequent. A low-calorie diet is recommended with the main goal of reducing intrahepatic fat infiltration, fat tissue and making easier the surgery. Information the use pharmacological interventions during the preoperative period in this population are rare.

NCT ID: NCT03849235 Recruiting - Cirrhosis Clinical Trials

A Pathophysiological Study of the Postprandial Human Liver (PLS)

PLS
Start date: March 2, 2019
Phase:
Study type: Observational

Fatty liver disease is a globally widespread disease The identification of valid biomarkers and targets for potential treatments requires in-depth knowledge about the pathophysiology of the postprandial liver. The study will consist of five work packages (WP) including blood tests and liver biopsies taken after fasting or ingestion of a standardized meal in: healthy controls (WP 1), patients with NAFLD (WP 2), and patients with cirrhosis (WP 3) ; before and after a standardised meal in healthy controls (WP 4), and before and after glucagon in healthy controls (WP5)

NCT ID: NCT03848390 Not yet recruiting - Clinical trials for Non-Alcoholic Fatty Liver Disease

Effect of Modified Time-restricted Feeding in Preventing Progression of Non-Alcoholic Fatty Liver Disease (NAFLD).

Start date: April 1, 2019
Phase: N/A
Study type: Interventional

The purpose of the study is to examine the effects of modified time-restricted feeding and conventional dietary approaches in motivated obese fatty liver patients on biochemical markers, imaging studies, and anthropometric measurements.

NCT ID: NCT03847116 Completed - Clinical trials for Type2 Diabetes Mellitus

Alcohol Consumption and Type 2 Diabetes Mellitus Risk in Nonalcoholic Fatty Liver Disease

Start date: January 1, 2009
Phase:
Study type: Observational

This study explored the cross-sectional and prospective associations between light-to-moderate alcohol consumption (LMAC) and risk of type 2 diabetes mellitus (T2DM) in individuals with nonalcoholic fatty liver disease (NAFLD).

NCT ID: NCT03844165 Recruiting - NAFLD Clinical Trials

Fighting Fatty Liver in India

FFL
Start date: January 1, 2019
Phase: N/A
Study type: Interventional

This study aims to build capacity in India by: 1. Developing tailored protocol methodologies for research including technical capability in imaging (MRI/S protocols & customised software), dietary intervention delivery, dietary evaluation, and biochemical analyses, using available local resources in Kerala. 2. Training and enhancing imaging skills of clinical radiographers in Kerala for research studies 3. Training local professionals and researchers in skills necessary to design, deploy and evaluate diet/lifestyle interventions, including patient engagement, in Kerala. This study will deliver and evaluate a simple dietary intervention pilot study in the Kerala region in conjunction with local nutritionists, healthcare professionals and partner researchers at PHRI (Population Health and Research Institute, Trivandrum, Kerala, India).